Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) vs Soren Acquisition Corp. (SORN)

A side-by-side comparison of Drugs Made In America Acquisition Corp. Ordinary Shares and Soren Acquisition Corp. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — DMAA vs SORN

growth of $100 · dividends reinvested · last 1y
DMAA +4.1% (+4.1%/yr)SORN +1.6% (+1.6%/yr)DMAA compounded faster over this window
100101102103104Start $100$104$102
DMAA SORN

DMAA vs SORN: by the numbers

  • •SORN is the larger company ($264M vs $263M market cap).
  • •DMAA trades at the lower trailing earnings multiple (55.22 vs 90.93 P/E), one valuation lens rather than an overall verdict.

Metrics side by side

Valuation

MetricDMAASORN
P/E ratio55.2290.93
P/B ratio1.91151.31

Profitability

MetricDMAASORN
Gross margin0.00%0.00%
Operating margin0.00%0.00%
Net margin0.00%0.00%
ROE4.42%183.78%
ROIC-1.82%-0.12%

Frequently asked

Which has the lower trailing P/E, DMAA or SORN?
DMAA has the lower trailing P/E: DMAA trades at 55.22 and SORN at 90.93. P/E is one valuation measure and does not by itself establish which business is cheaper.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.